| CIPAGLUCOSIDASE ALFA MIGLUSTAT |
Pombiliti® Opfolda® |
AMICUS THERAPEUTICS PTY LTD |
Late onset Pompe disease |
Mar 2025 |
Not Recommended |
| NATALIZUMAB |
Tyruko® |
SANDOZ PTY LTD |
Relapsing-remitting multiple sclerosis (RRMS) |
Mar 2025 |
Recommended |
| USTEKINUMAB |
Epyztek® |
SAMSUNG BIOEPIS AU PTY LTD |
Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex
refractory fistulising Crohn disease |
Mar 2025 |
Recommended |
| ELACESTRANT |
Orserdu® |
A. MENARINI AUSTRALIA PTY LTD |
Estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative
(HER2-) locally advanced or metastatic breast cancer |
Mar 2025 |
Not Recommended |
| MIDOSTAURIN |
Rydapt® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |
Advanced systemic mastocytosis |
Mar 2025 |
Recommended |
| DAPSONE |
Dapsomed® |
MEDSURGE HEALTHCARE PTY LTD |
Dermatitis herpetiformis Leprosy Actinomycotic mycetoma |
Mar 2025 |
Recommended |
| SACITUZUMAB GOVITECAN |
Trodelvy® |
GILEAD SCIENCES PTY LIMITED |
Breast cancer |
Mar 2025 |
Not Recommended |
| TEPROTUMUMAB |
Tepezza® |
AMGEN AUSTRALIA PTY LTD |
Thyroid eye disease |
Mar 2025 |
Not Recommended |
| BULEVIRTIDE |
Hepcludex® |
GILEAD SCIENCES PTY LTD |
Chronic hepatitis D |
Mar 2025 |
Deferred |
| TARLATAMAB |
Imdelltra® |
AMGEN AUSTRALIA PTY LTD |
Small cell lung cancer |
Mar 2025 |
Not Applicable |
| FARICIMAB |
Vabysmo® |
ROCHE PRODUCTS PTY LTD |
Macular oedema secondary to retinal vein occlusion (RVO) |
Mar 2025 |
Recommended |
| PALOPEGTERIPARATIDE |
Yorvipath® |
SPECIALISED THERAPEUTICS PHARMA PTY LTD |
Chronic hypoparathyroidism |
Mar 2025 |
Not Recommended |
| PERTUZUMAB |
Perjeta® |
ROCHE PRODUCTS PTY LTD |
Human epidermal growth factor receptor 2-positive (HER2+) locally advanced, inflammatory
or early stage breast cancer |
Mar 2025 |
Recommended |
| MOGAMULIZUMAB |
Poteligeo® |
KYOWA KIRIN AUSTRALIA PTY LTD |
Cutaneous T-cell lymphoma (CTCL) |
Mar 2025 |
Recommended |
| ELAFIBRANOR |
Iqirvo® |
IPSEN PTY LTD |
Primary Biliary Cholangitis |
Mar 2025 |
Recommended |
| EFGARTIGIMOD ALFA |
Vyvgart® |
ARGENX AUSTRALIA PTY LTD |
Generalised myasthenia gravis (gMG) |
Mar 2025 |
Recommended |
| DARATUMUMAB |
Darzalex® |
JANSSEN-CILAG PTY LTD |
Multiple myeloma |
Mar 2025 |
Recommended |
| OMALIZUMAB |
Xolair® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Uncontrolled severe asthma Uncontrolled severe allergic asthma Severe chronic spontaneous
urticaria |
Mar 2025 |
Recommended |
| OMAVELOXOLONE |
Skyclarys® |
BIOGEN AUSTRALIA PTY LTD |
Friedreich’s ataxia |
Mar 2025 |
Not Recommended |
| ZILUCOPLAN |
Zilbrysq® |
UCB AUSTRALIA PTY LTD |
Generalised myasthenia gravis (gMG) |
Mar 2025 |
Recommended |
| POLATUZUMAB VEDOTIN |
Polivy® |
ROCHE PRODUCTS PTY LTD |
Diffuse large B-cell lymphoma (DLBCL) |
Mar 2025 |
Recommended |
| SOTATERCEPT |
Winrevair® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Pulmonary arterial hypertension (PAH) |
Mar 2025 |
Not Recommended |
| DENOSUMAB |
Xgeva® |
AMGEN AUSTRALIA PTY LIMITED |
Giant cell tumour of bone; Bone metastases |
Mar 2025 |
Recommended |
| FUTIBATINIB |
Lytgobi® |
TAIHO PHARMA OCEANIA PTY LTD |
Bile duct cancer (cholangiocarcinoma) |
Mar 2025 |
Not Recommended |
| GEMCITABINE |
Gemcitabine Sandoz® |
SANDOZ PTY LTD |
Various cancers |
Mar 2025 |
Recommended |
| ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR |
Trikafta® |
VERTEX PHARMACEUTICALS (AUSTRALIA) PTY LTD |
Cystic fibrosis |
Mar 2025 |
Recommended |
| INFLIXIMAB |
Remsima® SC |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis
Severe chronic plaque psoriasis Severe Crohn disease Complex refractory fistulising
Crohn Disease Moderate to severe ulcerative colitis |
Mar 2025 |
Recommended |
| ROZANOLIXIZUMAB |
Rystiggo® |
UCB AUSTRALIA PTY LTD |
Generalised myasthenia gravis (gMG) |
Mar 2025 |
Recommended |
| TORIPALIMAB |
Zytorvi® |
DR REDDY'S LABORATORIES AUSTRALIA PTY LTD |
Nasopharyngeal carcinoma |
Mar 2025 |
Recommended |
| ODEVIXIBAT |
Bylvay® |
IPSEN PTY LTD |
Progressive familial intrahepatic cholestasis (PFIC) |
Mar 2025 |
Deferred |
| RAVULIZUMAB |
Ultomiris® |
ALEXION PHARMACEUTICALS AUSTRALIASIA PTY LTD |
Generalised myasthenia gravis (gMG) |
Mar 2025 |
Recommended |
| FEZOLINETANT |
Veoza® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Moderate to severe menopause-related vasomotor symptoms |
Mar 2025 |
Not Recommended |
| ELRANATAMAB |
Elrexfio® |
PFIZER AUSTRALIA PTY LTD |
Relapsed or refractory multiple myeloma (RRMM) |
Mar 2025 |
Recommended |
| LUMASIRAN |
Oxlumo® |
MEDISON PHARMA AUSTRALIA PTY LTD |
Primary hyperoxaluria type 1 |
Mar 2025 |
Recommended |
| EFLORNITHINE |
Ifinwil® |
NORGINE PTY LTD |
Neuroblastoma |
Mar 2025 |
Recommended |
| AMIVANTAMAB LAZERTINIB |
Rybrevant® Lazcluze® |
JANSSEN-CILAG PTY LTD |
Non-small cell lung cancer (NSCLC) |
Mar 2025 |
Not Recommended |
| RUXOLITINIB |
Jakavi® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |
Polycythemia vera (PV) |
Mar 2025 |
Recommended |
| DUPILUMAB |
Dupixent® |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Severe atopic dermatitis Uncontrolled severe asthma |
Mar 2025 |
Recommended |
| ESTETROL WITH DROSPIRENONE |
Nextstellis® |
MAYNE PHARMA INTERNATIONAL PTY LTD |
Contraception |
Mar 2025 |
Recommended |
| IVACAFTOR |
Kalydeco® |
VERTEX PHARMACEUTICALS (AUSTRALIA) PTY LTD |
Cystic fibrosis (CF) |
Mar 2025 |
Recommended |
| DABRAFENIB TRAMETINIB |
Tafinlar® Mekinist® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |
Non-small cell lung cancer (NSCLC) |
Mar 2025 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Cervical cancer |
Mar 2025 |
Recommended |
| OMALIZUMAB |
Omlyclo® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Uncontrolled severe asthma Uncontrolled severe allergic asthma Severe chronic spontaneous
urticaria |
Mar 2025 |
Recommended |
| ZOLBETUXIMAB |
Vyloy® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Gastric or gastroesophageal junction (G/GOJ) cancer |
Mar 2025 |
Deferred |
| INFLIXIMAB |
Ixifi® |
PFIZER AUSTRALIA PTY LTD |
Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis
Severe chronic plaque psoriasis Severe Crohn disease, Complex refractory fistulising
Crohn Disease Moderate to severe ulcerative colitis |
Mar 2025 |
Recommended |
| CAPIVASERTIB |
Truqap® |
ASTRAZENECA PTY LTD |
Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative
(HER2-) locally advanced (unresectable) or metastatic breast cancer |
Mar 2025 |
Recommended |